
Deutsche Bank analyst Emmanuel Papadakis downgraded Swedish Orphan Biovitrum (BIOVF) to Hold from Buy with a SEK 515 price target Published first on TheFly – the ultimate source for real-time,
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| BIOVF | Swedish Orphan Biovitrum AB | 51.05 | 11.62 | 29.48% |
| Name | Price | % Change | |
|---|---|---|---|
| $51.05 | +29.48% |

Deutsche Bank analyst Emmanuel Papadakis downgraded Swedish Orphan Biovitrum (BIOVF) to Hold from Buy with a SEK 515 price target Published first on TheFly – the ultimate source for real-time,

Berenberg Bank analyst Harry Gillis has maintained their bullish stance on 0MTD stock, giving a Buy rating yesterday. Harry Gillis’s rating is based on Sobi’s strong third-quarter execution, which exceeded

Analyst Mitchell Kapoor from H.C. Wainwright reiterated a Buy rating on Swedish Orphan Biovitrum AB and keeping the price target at SEK600.00. Mitchell Kapoor gave his rating based on several

Swedish Orphan Biovitrum AB ( ($SE:SOBI) ) just unveiled an announcement. Swedish Orphan Biovitrum’s nomination committee has proposed former Ericsson chief executive Börje Ekholm as a new board member and

H.C. Wainwright raised the firm’s price target on Swedish Orphan Biovitrum (BIOVF) to SEK 600 from SEK 575 and keeps a Buy rating on the shares following the Q3 report.

Pareto analyst Filip Wiberg upgraded Swedish Orphan Biovitrum (BIOVF) to Buy from Hold with a SEK 530 price target Published first on TheFly – the ultimate source for real-time, market-moving

The latest update is out from Swedish Orphan Biovitrum AB ( ($SE:SOBI) ). Swedish Orphan Biovitrum AB (Sobi) reported another quarter of robust growth in the three months to September,

Swedish Orphan Biovitrum Ab (0MTD) is scheduled to report 3rd quarter earnings on 10/27/2026, before the market opens. Regarding Q3 estimates, Wall Street analysts expect Swedish Orphan Biovitrum Ab to

Nordea downgraded Swedish Orphan Biovitrum (BIOVF) to Hold from Buy. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today’s best-performing stocks

In a report released yesterday, Harry Gillis from Berenberg Bank maintained a Buy rating on Swedish Orphan Biovitrum AB, with a price target of SEK570.00. Harry Gillis has given his
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Feb 4, 2027Before Open | $15.83B | $0.67 | $974.76M | -2.73 | 24.45 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.